Cost-Effectiveness of Dimethyl Fumarate Treatment for Relapsing-Remitting Multiple Sclerosis From A Danish Perspective

Value in Health ◽

10.1016/j.jval.2015.09.2469 ◽

2015 ◽

Vol 18 (7) ◽

pp. A758 ◽

Author(s):

J Olsen ◽

A Wiren

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Value in Health ◽

10.1016/j.jval.2013.08.1826 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623 ◽

Author(s):

W. Su ◽

A. Walker ◽

S. Sarda ◽

A.R. Kansal ◽

C. Vicente ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.03.356 ◽

2014 ◽

Vol 17 (3) ◽

pp. A60-A61 ◽

Author(s):

J.A. Mauskopf ◽

M. Fay ◽

R. Iyer ◽

T. Livingston

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2015.09.2598 ◽

2015 ◽

Vol 18 (7) ◽

pp. A697 ◽

Author(s):

G Furneri ◽

L Santoni ◽

C Marchesi ◽

S Iannazzo ◽

P Cortesi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

Journal of Medical Economics ◽

10.3111/13696998.2016.1164174 ◽

2016 ◽

Vol 19 (7) ◽

pp. 718-727 ◽

Author(s):

Wenqing Su ◽

Anuraag Kansal ◽

Colin Vicente ◽

Baris Deniz ◽

Sujata Sarda

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Versus Glatiramer Acetate For The Treatment Of Relapsing-Remitting Multiple Sclerosis In The Chilean National Health Fund (Fonasa)

Value in Health ◽

10.1016/j.jval.2016.09.491 ◽

2016 ◽

Vol 19 (7) ◽

pp. A431

Author(s):

C Noda ◽

JA de Anda ◽

P Anaya ◽

P Serafini ◽

M Machado

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

National Health ◽

Dimethyl Fumarate ◽

Health Fund ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2019.09.1794 ◽

2019 ◽

Vol 22 ◽

pp. S740-S741

Author(s):

L.G. Mantovani ◽

G. Furneri ◽

P.A. Cortesi ◽

E. Puma ◽

L. Santoni ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Of Fingolimod, Teriflunomide, Dimethyl Fumarate And Intramuscular Interferon Beta-1a In Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.03.351 ◽

2014 ◽

Vol 17 (3) ◽

pp. A59-A60 ◽

Author(s):

X. Zhang ◽

J.W. Hay

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The Cost-Effectiveness Of Delayed Release Dimethyl Fumarate Versus Glatiramer Acetate For The Treatment Of Relapsing-Remitting Multiple Sclerosis In The Mexican Social Security Institute (Imss)

Value in Health ◽

10.1016/j.jval.2016.09.494 ◽

2016 ◽

Vol 19 (7) ◽

pp. A432

Author(s):

JA de Anda ◽

C Noda ◽

P Anaya ◽

A Azamar ◽

M Machado ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Social Security ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis ◽

Social Security Institute

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2015.09.2931 ◽

2015 ◽

Vol 18 (7) ◽

pp. A755 ◽

Author(s):

D Gasche ◽

G Restovic ◽

V Casado ◽

P Ramírez-Boix ◽

J Martínez Lopez

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis

CNS Drugs ◽

10.1007/s40263-014-0207-x ◽

2014 ◽

Vol 29 (1) ◽

pp. 71-81 ◽

Author(s):

Xinke Zhang ◽

Joel W. Hay ◽

Xiaoli Niu

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text